M&G PLC Purchases 766,992 Shares of Bruker Corporation $BRKR

M&G PLC raised its position in shares of Bruker Corporation (NASDAQ:BRKR) by 233.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,096,226 shares of the medical research company’s stock after purchasing an additional 766,992 shares during the quarter. M&G PLC owned 0.72% of Bruker worth $35,079,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Orbis Allan Gray Ltd bought a new stake in Bruker during the second quarter valued at approximately $192,735,000. AQR Capital Management LLC grew its position in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares during the period. Sculptor Capital LP increased its stake in shares of Bruker by 18.3% in the 2nd quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after purchasing an additional 476,363 shares in the last quarter. Brown Advisory Inc. raised its holdings in Bruker by 13.9% in the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after purchasing an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. lifted its position in Bruker by 61.6% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after purchasing an additional 796,510 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker News Summary

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Q4 revenue beat and conservative upside in full‑year revenue guidance — Bruker reported Q4 revenue of $977.2M, above consensus, and issued FY2026 revenue guidance of about $3.6B (above street revenue consensus), which supports top‑line growth expectations. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Strategic partnership in India to expand spatial biology presence — Bruker partnered with Premas Life Sciences to strengthen tissue research capabilities in India, which could support regional growth and recurring consumable/service revenue. Premas Life Sciences Partners with Bruker Spatial Biology
• Neutral Sentiment: Company released earnings presentation and slide deck — management’s slides and call are available for detail on segments and margin outlook; useful for judging whether revenue guidance is sustainable. Earnings Call Presentation
• Neutral Sentiment: Short‑interest data reported but appears anomalous — filings in mid‑February show zero shares/NaN changes (likely data/reporting noise), so don’t read meaningfully into a short squeeze risk from these entries.
• Negative Sentiment: EPS missed expectations and earnings declined year‑over‑year — Q4 EPS was $0.59 vs. consensus ~$0.65 and vs. $0.76 a year ago, highlighting near‑term margin pressure. Q4 Earnings Miss
• Negative Sentiment: Analysts trimmed forecasts and price targets after the print — multiple analysts lowered estimates and TD Cowen cut its price target from $53 to $43 and moved to a “hold,” which likely pressured the stock. These Analysts Cut Their Forecasts On Bruker TD Cowen note (summary)

Bruker Stock Performance

Shares of NASDAQ BRKR opened at $36.51 on Monday. The company has a market cap of $5.55 billion, a P/E ratio of -243.40, a P/E/G ratio of 4.78 and a beta of 1.19. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The firm’s fifty day moving average is $46.92 and its two-hundred day moving average is $40.48.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The firm had revenue of $977.20 million during the quarter, compared to analysts’ expectations of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts anticipate that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BRKR. Rothschild & Co Redburn set a $60.00 price objective on Bruker in a research note on Thursday, November 20th. JPMorgan Chase & Co. lifted their price target on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Wells Fargo & Company upped their price target on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. UBS Group restated a “neutral” rating and set a $49.00 target price on shares of Bruker in a research note on Friday. Finally, Jefferies Financial Group set a $50.00 price target on Bruker in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Bruker has an average rating of “Hold” and a consensus target price of $50.38.

Insider Activity at Bruker

In related news, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at $7,064,365. This represents a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 27.30% of the company’s stock.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.